Interleukin-1 beta secretion pathway (IL-1β secretion pathway)

The Interleukin-1 beta (IL-1β) secretion pathway is a specialized biological process responsible for the maturation and release of one of the most potent pro-inflammatory cytokines in the human body (NIH, 2025). Unlike most secreted proteins, IL-1β is synthesized as an inactive 31 kDa precursor (pro-IL-1β) that lacks a traditional signal sequence for the ER-Golgi secretory route (PubMed, 1990). Its activation typically requires a two-signal mechanism: a priming signal (e.g., via Toll-like receptors) to induce gene expression and an activation signal that triggers the assembly of an inflammasome complex, such as NLRP3 (NIH, 2011). The inflammasome activates Caspase-1, which cleaves pro-IL-1β into its active 17 kDa form and simultaneously cleaves Gasdermin D to create plasma membrane pores for cytokine release or pyroptotic cell death (Frontiers in Immunology, 2019). This pathway is a major driver of systemic and local inflammation, and its dysregulation is implicated in a wide range of conditions, from rare autoinflammatory syndromes like Muckle-Wells syndrome to common chronic diseases like atherosclerosis, gout, and type 2 diabetes (Blood Journal, 2011; ResearchGate, 2012). Therapeutic intervention in this pathway, primarily through IL-1β neutralization (e.g., canakinumab) or receptor blockade (e.g., anakinra), has shown significant clinical benefit in reducing inflammatory burden, though it is associated with an increased risk of serious infections (NIH, 2024).

Other names

IL-1β release pathwayNon-conventional IL-1β secretionInflammasome-mediated IL-1β secretionIL-1β maturation and release pathway

Inhibition of the IL-1β signaling axis through direct cytokine neutralization, receptor antagonism, or blockade of upstream processing by the NLRP3 inflammasome and Caspase-1.